Experienced in POEMS Syndrome

Dr. Christopher E. Dittus

Hematology Oncology | Emergency Medicine | Hematology
University Of North Carolina At Chapel Hill
101 Manning Dr, 
Chapel Hill, NC 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Offers Telehealth
17 Years of Experience
Experienced in POEMS Syndrome
University Of North Carolina At Chapel Hill
101 Manning Dr, 
Chapel Hill, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Christopher Dittus is a Hematologist Oncology specialist and an Emergency Medicine provider in Chapel Hill, North Carolina. Dr. Dittus has been practicing medicine for over 17 years and is rated as an Experienced provider by MediFind in the treatment of POEMS Syndrome. His top areas of expertise are Non-Hodgkin Lymphoma, Mantle Cell Lymphoma (MCL), Waldenstrom Macroglobulinemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Dittus is currently accepting new patients.

His clinical research consists of co-authoring 35 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of POEMS Syndrome.

Graduate Year
2009
Specialties
Hematology Oncology
Emergency Medicine
Hematology
Licenses
Emergency Medicine in MA
Hospital Affiliations
Unc Hospitals
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
FirstCarolinaCare
  • HMO
  • MEDICARE MAPD
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Trillium
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
101 Manning Dr, Chapel Hill, NC 27514

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Phase Ib/II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Hodgkin's Lymphoma and CD30+ Non-Hodgkin's Lymphoma
Phase Ib/II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Hodgkin's Lymphoma and CD30+ Non-Hodgkin's Lymphoma
Enrollment Status: Recruiting
Publish Date: October 14, 2025
Intervention Type: Biological
Study Drug: ATLCAR.CD30 cells
Study Phase: Phase 1/Phase 2
Phase II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Peripheral T Cell Lymphoma
Phase II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Peripheral T Cell Lymphoma
Enrollment Status: Recruiting
Publish Date: September 22, 2025
Intervention Type: Biological, Drug
Study Drugs: ATLCAR.CD30 T cells, Bendamustine, Fludarabine, Cyclophosphamide
Study Phase: Phase 2
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Drug, Biological, Procedure
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Prednisone, Rituximab, Venetoclax, Vincristine Sulfate
Study Phase: Phase 2/Phase 3
A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas
A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: July 18, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Filgrastim, Ibrutinib, Pegfilgrastim, Prednisone, Rituximab, Vincristine Sulfate
Study Phase: Phase 1
A Phase 1B Trial Nivolumab Consolidation Following Completion of High-Dose Methotrexate Containing Induction Chemotherapy in Older (≥ 65) Patients With Primary CNS Lymphoma
A Phase 1B Trial Nivolumab Consolidation Following Completion of High-Dose Methotrexate Containing Induction Chemotherapy in Older (≥ 65) Patients With Primary CNS Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: July 09, 2025
Intervention Type: Drug
Study Phase: Phase 1
Phase I Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Prevention of Relapse of CD30+ Lymphomas After High Dose Therapy and Autologous Stem Transplantation (ATLAS)
Phase I Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Prevention of Relapse of CD30+ Lymphomas After High Dose Therapy and Autologous Stem Transplantation (ATLAS)
Enrollment Status: Active_not_recruiting
Publish Date: May 15, 2025
Intervention Type: Drug
Study Drug: Anti-CD30 CAR-T Cells
Study Phase: Phase 1
Tissue Acquisition for Analysis of Prognostic Factors, Immunology, and Genetic Progression of HIV-1 Associated Malignancies
Tissue Acquisition for Analysis of Prognostic Factors, Immunology, and Genetic Progression of HIV-1 Associated Malignancies
Enrollment Status: Terminated
Publish Date: March 16, 2023
Intervention Type: Other, Genetic
A Randomized, Open-Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (19A+RICE) Chemotherapy vs. RICE in the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Candidates for Autologous Stem Cell Transplant
A Randomized, Open-Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (19A+RICE) Chemotherapy vs. RICE in the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Candidates for Autologous Stem Cell Transplant
Enrollment Status: Terminated
Publish Date: May 17, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
Enrollment Status: Completed
Publish Date: April 19, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 7 Less Clinical Trials

35 Total Publications

Update on paraproteinemic neuropathy.
Update on paraproteinemic neuropathy.
Journal: Current neurology and neuroscience reports
Published: June 16, 2025
Similar Doctors
Distinguished in POEMS Syndrome
Dr. Brandi N. Reeves
Hematology Oncology | Hematology | Oncology
Distinguished in POEMS Syndrome
Dr. Brandi N. Reeves
Hematology Oncology | Hematology | Oncology

University Of North Carolina At Chapel Hill

101 Manning Dr, 
Chapel Hill, NC 
 (0.1 miles away)
984-974-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Brandi Reeves is a Hematologist Oncology specialist and a Hematologist in Chapel Hill, North Carolina. Dr. Reeves is rated as a Distinguished provider by MediFind in the treatment of POEMS Syndrome. Her top areas of expertise are Multiple Myeloma, Polycythemia Vera, Essential Thrombocythemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Reeves is currently accepting new patients.

Advanced in POEMS Syndrome
Dr. Yan S. Feng
Hematology Oncology | Hematology | Oncology
Advanced in POEMS Syndrome
Dr. Yan S. Feng
Hematology Oncology | Hematology | Oncology

The Moses H Cone Memorial Hospital Operating Corporation

501 N Elam Ave, 
Greensboro, NC 
 (44.9 miles away)
336-832-1100
Languages Spoken:
English, Mandarin
See accepted insurances
Accepting New Patients
Offers Telehealth

Yan Feng is a Hematologist Oncology specialist and a Hematologist in Greensboro, North Carolina. Dr. Feng is rated as a Distinguished provider by MediFind in the treatment of POEMS Syndrome. Her top areas of expertise are Familial Colorectal Cancer, Paget Disease of the Breast, Gastroesophageal Junction Cancer, and Anal Cancer. Dr. Feng is currently accepting new patients.

Distinguished in POEMS Syndrome
Dr. Thomas C. Shea
Hematology Oncology
Distinguished in POEMS Syndrome
Dr. Thomas C. Shea
Hematology Oncology
6013 Farrington Rd, 
Chapel Hill, NC 
 (4.0 miles away)
919-966-4191
Languages Spoken:
English

Thomas Shea is a Hematologist Oncology provider in Chapel Hill, North Carolina. Dr. Shea is rated as a Distinguished provider by MediFind in the treatment of POEMS Syndrome. His top areas of expertise are Non-Hodgkin Lymphoma, Multiple Myeloma, Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dittus's expertise for a condition
ConditionClose
    View All 15 Advanced Conditions
    View All 22 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile